N-butyl-2-methylimino-N-propyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-1,3-dihydro-1-benzazepine-4-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: N-butyl-2-methylimino-N-propyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-1,3-dihydro-1-benzazepine-4-carboxamide
• 化学式: C₃₀H₃₈N₄O₂
• 分子量: 486.6
• InChiKey: STGZMTCOKDKYHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Substituted Benzoazepines As Toll-Like Receptor Modulators
  申请人：Burgess Laurence E.

  公开号：US20140088085A1

  公开（公告）日：2014-03-27

  Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.

  提供的是用于调节Toll样受体TLR7和/或TLR8信号传导的组合物和方法。这些组合物和方法可用于治疗或预防疾病，包括癌症、自身免疫性疾病、纤维化疾病、心血管疾病、传染病、炎症性疾病、移植排斥或移植物抗宿主病。
• COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US20170056391A1

  公开（公告）日：2017-03-02

  The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
• ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US20170114137A1

  公开（公告）日：2017-04-27

  The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
• Anti PD-L1 Conjugates for Treating Tumors
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US20170290923A1

  公开（公告）日：2017-10-12

  The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.